Peroxisome proliferator-activated receptor gamma overexpression suppresses proliferation of human colon cancer cells

Biochemical and Biophysical Research Communications

Volumn 424, Issue 3, 2012, Pages 524-529

  Tsukahara, Tamotsu ^a   Haniu, Hisao ^a  

^a SHINSHU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Cell proliferation; Colon cancer; Gene overexpression; Peroxisome proliferator activated receptor gamma

Indexed keywords

MESSENGER RNA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA;

ARTICLE; CANCER CELL CULTURE; CELL PROLIFERATION; COLON CANCER; CONTROLLED STUDY; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

CACO-2 CELLS; CELL PROLIFERATION; CELL SURVIVAL; COLONIC NEOPLASMS; GENE EXPRESSION REGULATION, NEOPLASTIC; HT29 CELLS; HUMANS; PPAR GAMMA; RESPONSE ELEMENTS; TRANSCRIPTIONAL ACTIVATION;

EID: 84864763399     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2012.06.149     Document Type: Article

References (29)

1. Gallagher D.J., Kemeny N. Metastatic colorectal cancer: from improved survival to potential cure. Oncology 2010, 78:237-248.
2. Manzano A., Perez-Segura P. Colorectal cancer chemoprevention: is this the future of colorectal cancer prevention?. Sci. World J. 2012, 2012:327341.
3. ACS, Cancer Facts and Figures (Atlanta: American Cancer Society), Cancer Facts and Figures (Atlanta: American Cancer Society), 2012.
4. Van den Eynde M., Hendlisz A. Treatment of colorectal liver metastases: a review. Rev. Recent Clin. Trials 2009, 4:56-62.
5. Evans R.M. The nuclear receptor superfamily: a rosetta stone for physiology. Mol. Endocrinol. 2005, 19:1429-1438.
6. Tontonoz P., Hu E., Graves R.A., Budavari A.I., Spiegelman B.M. MPPAR gamma 2: tissue-specific regulator of an adipocyte enhancer. Gene Dev. 1994, 8:1224-1234.
7. Zhu Y., Qi C., Korenberg J.R., Chen X.N., Noya D., Rao M.S., Reddy J.K. Structural organization of mouse peroxisome proliferator-activated receptor gamma (mPPAR gamma) gene: alternative promoter use and different splicing yield two mPPAR gamma isoforms. Proc. Nat. Acad. Sci. USA 1995, 92:7921-7925.
8. Xue J.C., Schwarz E.J., Chawla A., Lazar M.A. Distinct stages in adipogenesis revealed by retinoid inhibition of differentiation after induction of PPARgamma. Mol. Cell. Biol. 1996, 16:1567-1575.
9. Asami-Miyagishi R., Iseki S., Usui M., Uchida K., Kubo H., Morita I. Expression and function of PPARgamma in rat placental development. Biochem. Biophys. Res. Commun. 2004, 315:497-501.
10. Medina-Gomez G., Virtue S., Lelliott C., Boiani R., Campbell M., Christodoulides C., Perrin C., Jimenez-Linan M., Blount M., Dixon J., Zahn D., Thresher R.R., Aparicio S., Carlton M., Colledge W.H., Kettunen M.I., Seppanen-Laakso T., Sethi J.K., O'Rahilly S., Brindle K., Cinti S., Oresic M., Burcelin R., Vidal-Puig A. The link between nutritional status and insulin sensitivity is dependent on the adipocyte-specific peroxisome proliferator-activated receptor-gamma2 isoform. Diabetes 2005, 54:1706-1716.
11. Sato H., Ishihara S., Kawashima K., Moriyama N., Suetsugu H., Kazumori H., Okuyama T., Rumi M.A., Fukuda R., Nagasue N., Kinoshita Y. Expression of peroxisome proliferator-activated receptor (PPAR)gamma in gastric cancer and inhibitory effects of PPARgamma agonists. Br. J. Cancer 2000, 83:1394-1400.
12. Yang W.L., Frucht H. Activation of the PPAR pathway induces apoptosis and COX-2 inhibition in HT-29 human colon cancer cells. Carcinogenesis 2001, 22:1379-1383.
13. Takahashi H., Hosono K., Uchiyama T., Sugiyama M., Sakai E., Endo H., Maeda S., Schaefer K.L., Nakagama H., Nakajima A. PPARgamma ligand as a promising candidate for colorectal cancer chemoprevention: a pilot study. PPAR Res. 2010, 10.1155/2010/257835.
14. Tsukahara T., Hanazawa S., Kobayashi T., Iwamoto Y., Murakami-Murofushi K. Cyclic phosphatidic acid decreases proliferation and survival of colon cancer cells by inhibiting peroxisome proliferator-activated receptor gamma. Prostaglandins Other Lipid Mediat. 2010, 93:126-133.
15. Tsukahara T. The role of PPARgamma in the transcriptional control by agonists and antagonists. PPAR Res. 2012, 2012:362361.
16. Schaefer K.L., Takahashi H., Morales V.M., Harris G., Barton S., Osawa E., Nakajima A., Saubermann L.J. PPARgamma inhibitors reduce tubulin protein levels by a PPARgamma, PPARdelta and proteasome-independent mechanism, resulting in cell cycle arrest, apoptosis and reduced metastasis of colorectal carcinoma cells. Int. J. Cancer 2007, 120:702-713.
17. Schaefer K.L., Wada K., Takahashi H., Matsuhashi N., Ohnishi S., Wolfe M.M., Turner J.R., Nakajima A., Borkan S.C., Saubermann L.J. Peroxisome proliferator-activated receptor gamma inhibition prevents adhesion to the extracellular matrix and induces anoikis in hepatocellular carcinoma cells. Cancer Res. 2005, 65:2251-2259.
18. Tachibana K., Yamasaki D., Ishimoto K., Doi T. The role of PPARs in cancer. PPAR Res. 2008, 2008:102737.
19. Allred C.D., Kilgore M.W. Selective activation of PPARgamma in breast, colon, and lung cancer cell lines. Mol. Cell. Endocrinol. 2005, 235:21-29.
20. Chintharlapalli S., Papineni S., Konopleva M., Andreef M., Samudio I., Safe S. 2-Cyano-3,12-dioxoolean-1,9-dien-28-oic acid and related compounds inhibit growth of colon cancer cells through peroxisome proliferator-activated receptor gamma-dependent and -independent pathways. Mol. Pharmacol. 2005, 68:119-128.
21. Chintharlapalli S., Papineni S., Safe S. 1,1-Bis(3'-indolyl)-1-(p-substituted phenyl)methanes inhibit colon cancer cell and tumor growth through PPARgamma-dependent and PPARgamma-independent pathways. Mol. Cancer Ther. 2006, 5:1362-1370.
22. Han S., Roman J. Rosiglitazone suppresses human lung carcinoma cell growth through PPARgamma-dependent and PPARgamma-independent signal pathways. Mol. Cancer Ther. 2006, 5:430-437.
23. Tsukahara T., Tsukahara R., Yasuda S., Makarova N., Valentine W.J., Allison P., Yuan H., Baker D.L., Li Z., Bittman R., Parrill A., Tigyi G. Different residues mediate recognition of 1-O-oleyllysophosphatidic acid and rosiglitazone in the ligand binding domain of peroxisome proliferator-activated receptor gamma. J. Biol. Chem. 2006, 281:3398-3407.
24. Tsukahara T., Tsukahara R., Fujiwara Y., Yue J., Cheng Y., Guo H., Bolen A., Zhang C., Balazs L., Re F., Du G., Frohman M.A., Baker D.L., Parrill A.L., Uchiyama A., Kobayashi T., Murakami-Murofushi K., Tigyi G. Phospholipase D2-dependent inhibition of the nuclear hormone receptor PPARgamma by cyclic phosphatidic acid. Mol. Cell 2010, 39:421-432.
25. DuBois R.N., Gupta R., Brockman J., Reddy B.S., Krakow S.L., Lazar M.A. The nuclear eicosanoid receptor, PPARgamma, is aberrantly expressed in colonic cancers. Carcinogenesis 1998, 19:49-53.
26. Murphy G.J., Holder J.C. PPAR-gamma agonists: therapeutic role in diabetes, inflammation and cancer. Trends Pharmacol. Sci. 2000, 21:469-474.
27. Sporn M.B., Suh N., Mangelsdorf D.J. Prospects for prevention and treatment of cancer with selective PPARgamma modulators (SPARMs). Trends Mol. Med. 2001, 7:395-400.
28. Bull A.W. The role of peroxisome proliferator-activated receptor gamma in colon cancer and inflammatory bowel disease. Arch. Pathol. Lab. Med. 2003, 127:1121-1123.
29. Ikezoe T., Miller C.W., Kawano S., Heaney A., Williamson E.A., Hisatake J., Green E., Hofmann W., Taguchi H., Koeffler H.P. Mutational analysis of the peroxisome proliferator-activated receptor gamma gene in human malignancies. Cancer Res. 2001, 61:5307-5310.